
VOLUME 18 | ISSUE 2 April 2013 ISSN: 1092-8529



journals.cambridge.org/cns

CNS SPECTRUMS

EDITOR-IN-CHIEF: STEPHEN M. STAHL





https://doi.org/10.1017/S1092852913000230 Published online by Cambridge University Press



Neuroscience Education Institute

> MAKE 2013 AN AMAZING YEAR FOR YOUR ADVANCEMENT IN MENTAL HEALTH CARE.

2013 NEI PSYCHO PHARMACOLOGY CONGRESS

COLORADO SPRINGS

NOVEMBER 14 - 17, 2013 Attend the premier psychopharmacology event of the year.

- Inspiring content
- Elite speakers
- Latest in treatment strategies
- Comfortable seating

Use promo code 2013EVENTS & get 10% off registration rates.*

Call us at

or visit

today!

1-888-535-5600

www.neiglobal.com



* Cannot be combined with other sales or promotions.

CNS SPECTRUMS

CONTENTS

BRAINSTORMS		ORIGINAL RESEARCH	
The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses Stephen M. Stahl	65	Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses Juliano S. Souza, Monica Kayo, Ivson Tassell, Camila Bertini Martins and Helio Elkis	82
EDITORIAL Posttraumatic stress disorder: what have we learned in 3000 years?		Attentional functioning in patients with posttraumatic stress disorder: a preliminary study Michael David Horner, Jacobo E. Mintzer, Travis H. Turner, Keith R. Edmiston and Olga Brawman-Mintzer	90
William M. Sauvé PTSD: past, present, and future Bret A. Moore	69 71	Cerebral basis of posttraumatic stress disorder following the Chernobyl disaster Konstantin N. Loganovsky and Nataliya A. Zdanevich	95
REVIEW ARTICLE Cognitive behavioral treatments for posttraumatic stress disorder: Empirical foundation and new directions Ellen M. Koucky, Benjamin D. Dickstein and Kathleen M. Chard	73	The efficacy of initial hydrocortisone administration at preventing posttraumatic distress in adult trauma patients: a randomized trial Douglas L. Delahanty, Crystal Gabert-Quillen, Sarah A. Ostrowski, Nicole R. Nugent, Beth Fischer, Adam Morris, Roger K. Pitman, John Bon and William Fallon, Jr.	103

Editor-in-Chief

Stephen M. Stahl, Adjunct Professor of Psychiatry at the University of California San Diego, USA; Honorary Visiting Senior Fellow at the University of Cambridge, UK.

Field Editors

Terence Arthur Ketter, Stanford University, USA Gerard Sanacora, Yale University School of Medicine, USA Carlos A. Zarate, National Institute of Mental Health, USA

Deputy Editor

Thomas L. Schwartz, SUNY Upstate Medical University in Syracuse, USA

Editorial Board

Dennis S. Charney, Mount Sinai School of Medicine, USA Maria Conceição do Rosario, University of São Paulo Medical School, Brazil Jeffrey L. Cummings, Cleveland Clinic, USA Thilo Deckersbach, Harvard Medical School, USA Koen Demyttenaere, University Psychiatric Center KuLeuven, Belgium Karen D. Ersche, University of Cambridge, UK Robert L. Findling, Case Western Reserve University, USA Mark S. George, Medical University of South Carolina, USA Eric Hollander, Albert Einstein College of Medicine and Montefiore Medical Center, USA Daphne Holt, Harvard Medical School, USA Peter B. Jones, University of Cambridge, UK Andres M. Kanner, University of Miami, USA Terence Arthur Ketter, Stanford University, USA Anthony D. Loebel, New York University School of Medicine, USA Donatella Marazziti, University of Pisa, Italy Herbert Y. Meltzer, Northwestern University, USA Mario F. Mendez, University of California, Los Angeles, USA Philip Mitchell, University of New South Wales, Australia Jun Nakamura, University of Occupational and Environmental Health, Japan Humberto Nicolini, National Mexican Institute of Psychiatry, Mexico Andrew A. Nierenberg, Harvard Medical School, USA Stefano Pallanti, University of Florence, Italy Katharine A. Phillips, Brown University, USA Diego A. Pizzagalli, Harvard Medical School, USA Mark H. Pollack, Rush University Medical Center, USA Mark H. Rapaport, Emory University, USA Irismar Reis de Oliveira, Universidade Federal da Bahia, Brazil Trevor W. Robbins, University of Cambridge, UK Peter P. Roy-Byrne, University of Washington School of Medicine, USA Barbara J. Sahakian, University of Cambridge, UK Gerard Sanacora, Yale University School of Medicine, USA Alan F. Schatzberg, Stanford University School of Medicine, USA Thomas E. Schlaepfer, University Hospital Bonn, Germany Thomas L. Schwartz, SUNY Upstate Medical University in Syracuse, USA Jordan W. Smoller, Harvard Medical School, USA Dan J. Stein, University of Cape Town (UCT), South Africa Stephen Strakowski, University of Cincinnati, USA T. Scott Stroup, Columbia University, USA Frank I. Tarazi, Harvard Medical School, USA Michael E. Thase, University of Pennsylvania, USA Michael Trimble, National Hospital for Neurology, Queen Square, London Madhukar H. Trivedi, University of Texas Southwestern Medical Center, USA Karen Dineen Wagner, The University of Texas Medical Branch, USA Katherine D. Warburton, Department of State Hospitals, USA Stephen R. Wisniewski, University of Pittsburgh, USA Shigeto Yamawaki, Hiroshima University, Japan Carlos A. Zarate, Jr., National Institute of Mental Health, USA Joseph Zohar, Tel Aviv University, Israel

Content Editor

Lisa Arrington, Cambridge University Press (larrington@cambridge.org)

Aims and Scope

CNS Spectrums aims to be the premiere journal covering all aspects of clinical neurosciences, neurotherapeutics and neurospsychopharmacology. From 2012 the journal will primarily focus on the publication of authoritative, cross-disciplinary

Cover Image: The image on the cover shows a hypothetical model whereby glutamate is released from an intracortical pyramidal neuron and binds to an NMDA receptor on a GABA-ergic interneuron. GABA is then released and binds to receptors on the axon of another glutamate pyramidal neuron. This inhibits the neuron, thus reducing the release of cortical glutamate. The GABA interneuron and its NMDA synapse from the first neuron to the second is the hypothetical site of glutamate dysfunction in schizophrenia.

Stahl's Essential Psychopharmacology, 4th edition, by Stephen M. Stahl Copyright © 2013 Stephen M. Stahl. Reproduced with permission.

review and opinion material publishing advances and controversial issues with pertinence to the clinician. In particular we aim to publish reviews and articles in translational neuroscience, biological psychiatry and neuropsychopharmacology that explain clinically relevant neuroscience discoveries in a way that makes these findings accessible and understandable to clinicians and clinical investigators. We will emphasize new therapeutics of all types in clinical neurosciences, mental health, psychiatry, and neurology, especially first in man studies and proof of concept studies. Our focus will be not just drugs, but novel psychotherapies and neurostimulation therapeutics as well. *CNS Spectrums* will in addition, continue to publish original research and commentaries that focus on emergent areas of research. Subject coverage shall span the full spectrum on neuropsychiatry focusing on translational issues and those crossing traditional boundaries between neurology and psychiatry.

Submitting Manuscripts to CNS Spectrums

All submissions to CNS Spectrums should be prepared in accordance with the instructions for authors and in the style of the Journal. Manuscripts should be submitted through the dedicated CNS Spectrums ScholarOne Manuscripts website: http://mc.manuscriptcentral.com/cnsspectr

CNS Spectrums will consider and encourage the following types of articles for publication: **Review Article**—Comprehensive article summarizing and synthesizing the literature on various topics presented in a scholarly and clinically relevant fashion; **Original Research**—Reports the results of a clinical study and contains original research; **Opinion**—Address a current topic of high interest, which has substantial evidence but has not yet been established; **Commentary**—An article that is written in reaction to previously published articles; usually encouraging a level of debate; the journal will also include **Brainstorms** and **Editorials** that shall be commissioned or written by the Editor in Chief.

Instructions for Contributors

The Instructions for Contributors are available on the Cambridge Journals Online web site at: http://journals.cambridge.org/CNSifc

Indexing

CNS Spectrums is indexed by Index Medicus/MEDLINE and Web of Science (Thomson Reuters) as well as appearing in the annual Journal Citation Report. Introduced in 1996, the journal was acquired in whole by Cambridge University Press in November of 2011.

Subscriptions

Institutional print and electronic: £474/\$750; Institutional electronic only: £362/\$578.

© Cambridge University Press 2013. All rights reserved.

No part of this publication may be reproduced, in any form or by any means, electronic, photocopying, or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: http://www.cambridge.org/rights/permissions/permission.htm. Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center http://www.copyright.com, email: info@copyright.com.

Rights & permissions requests can be applied for online within each article by clicking "Request Permissions" within the table of contents or in the fulltext version of a specific article. Requests will be processed via the CCC Rightslink system and processed immediately.

CNS Spectrums (ISSN: Print 1092-8529; eISSN: 2165-6509) is published bimonthly by Cambridge University Press.

Postmaster

Send address changes in the U.S.A., Canada, and Mexico to *CNS Spectrums*, Cambridge University Press, Journals Dept., 100 Brook Hill Drive, West Nyack, NY 10994-2133, U.S.A. Send address changes elsewhere to *CNS Spectrums*, Cambridge University Press, The Edinburgh Building, Shaftesbury Road, Cambridge CB2 8RU, England.

Online availability

CNS Spectrums is hosted on the Cambridge Journals Online (CJO) service at http://journals.cambridge.org/cns

Institutional subscribers: Access to full-text articles online is only granted to subscription options offering an online component. Subscriptions must be activated by the purchasing institution using the instructions provided at the time of purchase; see information for subscribers at: http://journals.cambridge.org/

Reprint and Advertising Sales

Inquiries for bulk reprint sales and placement of advertising should be sent to the Journals Sales Department of Cambridge University Press: USAdSales@cambridge.org


CAMBRIDGE

JOURNALS

The International Journal of **Neuropsychopharmacology**

EDITOR

Alan Frazer, University of Texas Health Science Center, San Antonio, USA



The International Journal of Neuropsychopharmacology (IJNP) serves as a major forum for the rapid publication and wide dissemination of high guality, influential research in neuropsychopharmacology, in the basic and clinical domains. The central focus of the journal is on research which advances understanding of existing and new neuropsychopharmacological agents, including their mode of action and clinical application, or which provides insights into the biological basis of neuropsychiatric disorders and thereby advances their pharmacological treatment. Such research might derive from the full spectrum of biological and psychological fields of inquiry, encompassing classical and novel techniques in neuropsychopharmacology, as well as strategies such as neuroimaging, genetics, psycho-neuroendocrinology and neuropsychology. IJNP's rapid publication policy is facilitated by web-based submission and review, and the journal publishes the definitive versions of papers online, ahead of the printed issues. All papers are indexed in PubMed and Thomson Reuters Journal Citation Reports.

FREE email alerts Keep up-to-date with new material – sign up at http://journals.cambridge.org/pnp-alerts

http://journals.cambridge.org/pnp



MBRIDGE

UNIVERSITY PRESS

https://doi.org/10.1017/S1092852913000230 Published online by Cambridge University Press